ARAY

Accuray is a genuine operating business — the CyberKnife and TomoTherapy/Radixact radiation-therapy platforms generate $459M of FY2025 revenue, and at a $28.7M market cap the stock trades at just 0.1x sales. On the surface that screams deep value, and the operating trend is the best part of the story: operating income swung to +$7.84M and the net loss narrowed ~90% to just -$1.59M. But a 0.1x P/S is the market pricing distress, not opportunity, and the balance sheet explains why. Liabilities are 4.79x equity, long-term plus current debt totals ~$137M against only $57.4M of cash (down 16.3% on the year), and the accumulated deficit sits at -$519M. This company has lost money every year shown — FY2021 through FY2025 — and funded itself in part by issuing stock, with shares up 12.4% year-over-year, diluting the tiny equity base further.

The filing language reinforces that the near-term picture is deteriorating, not healing. Management states that inflation, supply-chain and logistics costs have 'materially affected our gross margins and net income (loss)' and expects that pressure to continue 'through at least calendar year 2025, and potentially longer.' Critically for the top line, they warn that 'reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines, in the United States have negatively impacted our net revenue since fiscal year 2024, and we expect this will continue to have an impact through fiscal year 2026.' Layered on top is explicit tariff/China exposure: ~70% of raw materials are U.S.-sourced but over 80% of finished product is exported, and management flags 'significant tariff uncertainty' with 'incremental costs.' So the modest FY2025 profitability improvement runs straight into a guided revenue and margin headwind.